DEXMETHYLPHENIDATE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
| Metabolism | Dexmethylphenidate is primarily metabolized via deesterification to d-ritalinic acid, which has little to no pharmacological activity. The metabolism is mediated by carboxylesterase CES1A1. |
| Excretion | Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug) |
| Half-life | 2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations |
| Protein binding | 12-19% bound to plasma proteins, primarily albumin |
| Volume of Distribution | 3.3-4.8 L/kg; clinical meaning: indicates extensive tissue distribution and penetration into tissues including the brain |
| Bioavailability | Approximately 22-25% following oral administration (immediate-release) due to first-pass metabolism; extended-release formulations have similar bioavailability |
| Onset of Action | Immediate-release: 30-60 minutes orally; Extended-release: 1-2 hours orally |
| Duration of Action | Immediate-release: 3-6 hours; Extended-release: 8-12 hours; clinical notes: duration varies with formulation; tolerance may develop with chronic use |
| Molecular Weight | 269.8 |
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe impairment (CrCl <30 mL/min), reduce dose by 50%. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Avoid use or reduce dose by 75%. |
| Pediatric use | Children 6 years and older: Initial 5 mg once or twice daily (morning and noon); increase by 5 mg at weekly intervals; maximum 20 mg twice daily. Weight-based: 0.3 mg/kg/day divided twice daily, max 1 mg/kg/day. |
| Geriatric use | Start at 2.5 mg once daily in the morning; increase by 2.5 mg weekly as tolerated; maximum 20 mg twice daily. Monitor for insomnia, appetite loss, and cardiovascular effects. |
| 1st trimester | Insufficient human data; animal studies show increased risk of fetal skeletal and cardiovascular anomalies at doses equivalent to human therapeutic doses. Avoid use unless potential benefit outweighs risk. |
| 2nd trimester | Limited data; may cause fetal tachycardia and reduced uterine blood flow. Use only if clearly needed. |
| 3rd trimester | Risk of neonatal withdrawal (irritability, feeding problems) and possible growth restriction. Avoid use near term. |
Clinical note
MAOIs are contraindicated due to risk of hypertensive crisis May exacerbate pre-existing psychosis and cause peripheral vasculopathy.
| Placental transfer | Crosses the human placenta; cord blood levels are approximately 0.2-0.5 times maternal serum levels in ex vivo perfusion studies. |
| Breastfeeding | Excreted into human milk in small amounts; estimated infant dose is 0.2-0.7% of maternal weight-adjusted dose. Monitor infant for agitation, insomnia, and poor weight gain. Consider alternative therapy during breastfeeding if possible. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including dexmethylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence during therapy.
| Common Effects | narcolepsy |
| Serious Effects |
Hypersensitivity to methylphenidate or any excipientConcurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuationGlaucomaSevere hypertension or other significant cardiovascular disease (e.g., structural cardiac abnormalities, cardiomyopathy, serious arrhythmias)Hyperthyroidism or thyrotoxicosisAgitated states or severe anxietyTourette's syndrome or tics with history of stimulant-induced tics
| Precautions | Serious cardiovascular events (sudden death, stroke, myocardial infarction) in patients with pre-existing structural cardiac abnormalities or other serious heart problems., Blood pressure and heart rate increase; monitor closely in all patients, especially those with hypertension or tachycardia., Psychiatric adverse events (e.g., exacerbation of pre-existing psychosis, manic episodes, aggressive behavior) may occur., Long-term suppression of growth (weight and height) in children; monitor growth during treatment., Seizures: may lower seizure threshold in patients with prior seizure history or EEG abnormalities., Peripheral vasculopathy, including Raynaud's phenomenon: use with caution in patients with pre-existing vascular disorders., Visual disturbances (difficulty with accommodation, blurred vision) have been reported. |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Animal studies have shown teratogenic effects at doses 40 times the human dose. Human data is limited; however, first trimester exposure may be associated with a small increased risk of congenital heart defects. Second and third trimester exposure may increase risks of preterm delivery, low birth weight, and neonatal withdrawal syndrome. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain. Assess for signs of preterm labor and placental insufficiency. Fetal monitoring should include growth ultrasounds and nonstress testing in third trimester if continued use. Neonatal monitoring for withdrawal symptoms (including irritability, hyperphagia, and drowsiness) for 48 hours postpartum. |
| Fertility Effects | In animal studies, doses up to 20 mg/kg/day (approximately 40 times human dose) did not impair fertility in rats. Human data on fertility effects are lacking. Caution in patients planning pregnancy. |
| Food/Dietary | High-fat meals can delay absorption of extended-release formulations but do not affect overall exposure. Avoid excessive caffeine or stimulants as they may potentiate side effects. Alcohol can cause rapid release of extended-release forms, leading to potentially toxic concentrations. |
| Clinical Pearls | Dexmethylphenidate HCl, the d-threo enantiomer of methylphenidate, is twice as potent as racemic methylphenidate. It is indicated for ADHD and has a rapid onset (30-60 min) with a shorter duration (4-5 hours for immediate-release, 8-12 hours for extended-release). Monitor for growth suppression in children, and consider dose adjustments in renal impairment. Avoid use with MAOIs or within 14 days of discontinuation. Use with caution in patients with hypertension, glaucoma, or tic disorders. |
| Patient Advice | Take exactly as prescribed; do not crush or chew extended-release capsules. · Avoid alcohol; it may alter drug release and increase side effects. · May cause insomnia; take last dose earlier in the day. · Report chest pain, palpitations, or shortness of breath immediately. · May decrease appetite; maintain regular meals and monitor weight. · Store at room temperature away from moisture and heat. |